Adagene Inc. announced on September 3, 2025, the appointment of Dr. Axel Hoos as Executive Advisor. Dr. Hoos is recognized as an immuno-oncology pioneer, credited with creating the term 'Immuno-Oncology' and driving the clinical development of YERVOY® (Ipilimumab), the first FDA-approved immune checkpoint inhibitor. His extensive background includes leadership roles at Bristol-Myers Squibb and GSK, and he previously served as CEO of Scorpion Therapeutics, which was acquired by Eli Lilly in 2025 for up to $2.5 billion.
Dr. Hoos will provide invaluable guidance in the clinical development of anti-CTLA-4 therapy, a critical area for Adagene's lead candidate, ADG126. He noted that Adagene's pipeline, centered around CTLA-4, including ADG116 and the masked ADG126, may allow a broader utility of CTLA-4 targeting in cancer immunotherapy. He specifically highlighted that Adagene's programs could favorably shift the benefit/risk ratio of CTLA-4 targeting, enabling treatment for new populations like cold tumors such as MSS CRC.
Adagene's CEO, Peter Luo, emphasized that Dr. Hoos's leadership comes at a pivotal moment as the company advances ADG126 through key clinical development stages and expands its SAFEbody™ pipeline. This appointment further strengthens Adagene's team of Executive Advisors, bringing deep expertise to redefine the future of precision immunotherapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.